Suppr超能文献

基于尿激酶的导管挽救封管液:一名即将接受肾移植患者的病例

Urokinase-based lock solutions for catheter salvage: A case of an upcoming kidney transplant recipient.

作者信息

Xia Cong, Fan Junfen, Xu Chao, Hu Shouci, Ma Hongzhen, He Lingzhi, Ye Liqing

机构信息

Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.

Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 54 You-Dian Road, Hangzhou, China.

出版信息

Open Med (Wars). 2023 Apr 13;18(1):20230699. doi: 10.1515/med-2023-0699. eCollection 2023.

Abstract

Catheter-related bloodstream infection (CRBSI) is a significant complication among patients on haemodialysis (HD) who are dependent on a central venous catheter (CVC) for an extended period. Catheter removal as first-line treatment can induce accelerated venous access site depletion in patients on HD who rely on it to survive. It is possible to retain the catheter in stable patients without septic syndrome while administering systemic antibiotics and antibiotic lock therapy. Herein, we report the case of a patient on HD with CRBSI who was successfully treated with intravenous levofloxacin- and urokinase-based antibiotic lock, without catheter removal prior to kidney transplantation. The use of urokinase in combination with antibiotics in lock solutions for treating catheter infections is rare. We verified the physical compatibility of levofloxacin and urokinase by visual inspection, turbidimetric measurements, and particle count. To our knowledge, this was a rare case demonstrating the effective use of urokinase and levofloxacin in a catheter lock for CRBSI in a patient on HD. Considering the need for highly concentrated antimicrobials and the availability of various antibiotics, the compatibility and stability of the lock solution is a matter of concern. Further studies are warranted to assess the stability and compatibility of various antibiotics in combination with urokinase.

摘要

导管相关血流感染(CRBSI)是长期依赖中心静脉导管(CVC)进行血液透析(HD)的患者的一种重要并发症。作为一线治疗方法的导管拔除,可能会导致依赖其维持生命的HD患者静脉通路部位加速耗竭。对于没有脓毒症综合征的稳定患者,在给予全身抗生素和抗生素封管治疗的同时,保留导管是可行的。在此,我们报告一例HD合并CRBSI的患者,该患者在肾移植前未拔除导管,而是成功接受了基于静脉注射左氧氟沙星和尿激酶的抗生素封管治疗。在封管溶液中使用尿激酶联合抗生素治疗导管感染的情况很少见。我们通过目视检查、比浊法测量和颗粒计数验证了左氧氟沙星和尿激酶的物理相容性。据我们所知,这是一例罕见病例,证明了尿激酶和左氧氟沙星在HD患者CRBSI导管封管中的有效应用。考虑到需要高浓度抗菌药物以及各种抗生素的可得性,封管溶液的相容性和稳定性是一个值得关注的问题。有必要进一步研究评估各种抗生素与尿激酶联合使用时的稳定性和相容性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dae9/10105553/0764e1dcd62f/j_med-2023-0699-fig004.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验